SCHEMBL9900080

SCHEMBL9900080

CC(=O)Nc1cc[c]c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
HSD17B10 Q99714 2/20 0.46
CYP1A2 P05177 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NAPRT Q6XQN6 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
MAPT P10636 2/20 0.43
RAB9A P51151 2/20 0.43
POLB P06746 2/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
GLA P06280 1/20 0.43
TNNI3 P19429 1/20 0.43
TNNT2 P45379 1/20 0.43
TNNC1 P63316 1/20 0.43
RUNX1 Q01196 1/20 0.43
CBFB Q13951 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10344806 0.81 APEX1 (0.50) HTTTSHR
SCHEMBL7841883 0.79 ALDH1A1 (0.47) ALDH1A1HSD17B10CYP1A2L3MBTL1HTT
SCHEMBL28100309 0.79 ALDH1A1 (0.55) ALDH1A1HSD17B10CYP1A2L3MBTL1HTT
SCHEMBL4066831 0.79 HSD17B10 (0.52) ALDH1A1HSD17B10CYP1A2L3MBTL1HTT
SCHEMBL7406905 0.79 ALDH1A1 (0.52) ALDH1A1HSD17B10CYP1A2L3MBTL1HTT
SCHEMBL9645353 0.78 ALDH1A1 (0.46) ALDH1A1HSD17B10CYP1A2L3MBTL1HTT
SCHEMBL2459851 0.78 ALDH1A1 (0.47) ALDH1A1HSD17B10CYP1A2L3MBTL1HTT
SCHEMBL5454303 0.77 L3MBTL1 (0.49) ALDH1A1HSD17B10CYP1A2L3MBTL1SMN1; SMN2
SCHEMBL3913097 0.76 HSD17B10 (0.47) ALDH1A1HSD17B10CYP1A2L3MBTL1HTT
SCHEMBL19304826 0.76 LMNA (0.54) ALDH1A1HSD17B10CYP1A2L3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US claimed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US claimed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 EP claimed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO claimed
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US disclosed
EP-2796456-A1 Bicyclic compounds as Pim inhibitors Amgen Inc. (US) 2014-10-29 EP disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US disclosed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 EP disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 ALDH1A1 502/4885HSD17B10 2341/4885CYP1A2 853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.